

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

	Application Number	10/642,462	
	Filing Date	August 15, 2003	
	First Named Inventor	Piomelli, Daniele	
	Art Unit	1623	
	Examiner Name	To Be Assigned	
Total Number of Pages in This Submission	9	Attorney Docket Number	02307E-125510US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): References (72); Return Postcard.
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP Frank J. Mycroft	Reg. No. 46,946
Signature		
Date	March 15, 2004	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Jose Luna		
Signature		Date	March 15, 2004



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On 3/15/04

TOWNSEND and TOWNSEND and CREW LLP

By: *[Signature]*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Daniele Piomelli, et al.

Application No.: 10/642,462

Filed: August 15, 2003

For: COMBINATION THERAPY FOR
CONTROLLING APPETITES

Examiner: To Be Assigned

Art Unit: To Be Assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with the Office's waiver, issued in the August 5, 2003 Official Gazette, copies of the cited U.S. patents and published patent applications are not submitted herewith. Copies of all other references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicants would also like to bring to the attention of the Examiner the following related pending patent applications: U.S. Patent Application No. 10/112,509, filed March 27,


PATENT
Attorney Docket No.: 02307E-125510US
Client Reference No.: UC Case No. 2002-408-2

2002, Publication No. 2003/0018081 (Attorney Docket No. 02307E-121300US), U.S. Patent Application No. 10/681,858, filed October 7, 2003 (Attorney Docket No. 02307E-127510US), and U.S. Patent Application No. 60/485,062, filed July 2, 2003 (Attorney Docket No. 02307E-133300US). The Examiner is respectfully requested to make these documents of record in the subject application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
FJM:jvl
60158249 v1



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	6	Application Number	10/642,462
-------	---	----	---	--------------------	------------

Complete if Known

Filing Date	August 15, 2003
First Named Inventor	Piomelli, Daniele
Art Unit	1623
Examiner Name	To Be Assigned
Attorney Docket Number	02307E-125510US

U.S. PATENT DOCUMENTS*

Examiner Initials*	Cite No.	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1.	5,596,106	A	01-21-1997	Cullinan et al.	
	2.	5,747,524		05-05-1998	Cullinan et al.	
	3.	5,847,008		12-08-1998	Doebber	
	4.	5,859,051		06-12-1999	Adams	
	5.	5,925,672		07-20-1999	Piomelli	
	6.	5,925,768	A	07-20-1999	Barth et al.	
	7.	5,962,012	A	10-05-1999	Lin	
	8.	5,985,282		11-18-1999	Haveson	
	9.	6,017,919	A	01-25-2000	Inaba et al.	
	10.	6,026,084		02-22-2000	Barth et al.	
	11.	6,068,978		05-30-2000	Briggs et al.	
	12.	6,090,836		07-18-2000	Adams	
	13.	6,090,839	A	07-18-2000	Adams	
	14.	6,096,784		08-01-2000	Lerner	
	15.	6,160,000		12-12-2000	Adams	
	16.	6,200,998		03-13-2001	Sahoo	
	17.	6,261,595		07-17-2001	Stanley	
	18.	6,271,015	B1	08-07-2001	Glula	
	19.	6,274,608	B1	08-14-2002	Sauerberg	
	20.	6,344,474		02-06-2002	Marusni et al.	
	21.	6,348,498	B1	02-19-2002	Calignano	
	22.	2001/0053788	A1	12-20-2001	Lange et al.	
	23.	2002/0035150	A1	03-21-2002	Piomelli	
	24.	2003/0149082	A1	06-07-2003	Makriyannis et al.	
	25.	2003/0018081		01-23-2003	Piomelli et al.	
	26.	2003/0041340		02-27-2003	Cravatt	
	27.	2003/0195226	A1	10-16-2003	Sit et al.	
	28.	10/681,858		N/A (Filed 10-07-2003)	Piomelli et al.	
	29.	60/485,062		N/A (Filed 07-02-2003)	Fu et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	30.	EP	0 576 357	B1	12-29-1993	Sanofi		<input type="checkbox"/>
	31.	EP	0 656 354	A1	06-07-1995	Sanofi		<input type="checkbox"/>
	32.	WO	97/36579	A1	10-09-1997	Willson		<input type="checkbox"/>
	33.	WO	97/27657	A1	08-07-1997	Adams		<input type="checkbox"/>
	34.	WO	97/28149	A1	08-07-1997	Liebowitz		<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁷ Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/642,462		
		Filing Date	August 15, 2003		
		First Named Inventor	Piomelli, Daniele		
		Art Unit	1623		
		Examiner Name	To Be Assigned		
Sheet	2	of	6	Attorney Docket Number	02307E-125510US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	35.	WO	98/20119	A1	05-14-1998	Gilula		<input type="checkbox"/>
	36.	WO	98/24396	A1	06-11-1998	Piomelli		<input type="checkbox"/>
	37.	WO	02/080660	A2	10-17-2002	UC Regents		<input type="checkbox"/>
	38.	WO	02/080903	A1	10-2002	University of Illinois		<input type="checkbox"/>
	39.	WO	02/100403	A1	12-19-2002	Eli Lilly and Co.		<input type="checkbox"/>
	40.	WO	03/000182	A2	01-03-2003	Merck & Co.		<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60158248

Copied from 10680373 on 07/23/2007

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/642,462
		Filing Date	August 15, 2003
		First Named Inventor	Piomelli, Daniele
		Art Unit	1623
		Examiner Name	To Be Assigned
		Attorney Docket Number	02307E-125510US
Sheet	3	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	41.	AHERN, G., "Activation of TRPV1 by the satiety factor oleylethanolamide" J. Biological Chemistry 278(33):30429-30434 (Aug. 15, 2003)	
	42.	AUBOEUVE, D. et al., "Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferators-activated receptors and liver X receptor- α in humans" Diabetes 46:1319-1327 (1997)	
	43.	BACHUR, N. et al., "Fatty Acid Amides of Ethanolamine in Mammalian Tissues," J. Biol. Chem., (1965), Vol. 240, No. 3, pp. 1019-1024.	
	44.	BERDYSHEV, E. et al., "Strass-induced generation of IN-acyl ethanolamines in mouse epidermal JB6 P+ cells," Biochem. J., (2000), Vol. 346, pp. 369-374.	
	45.	BERGER, J. and D. MOLLER, "The mechanisms of action of PPARs" Annu Rev Med 53:409-35 (2002)	
	46.	BOGER, D. et al., "Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide," PNAS, (2000), Vol. 97, No. 10, pp. 5044-5049.	
	47.	CADAS, H. et al., "Biosynthesis of an Endogenous Cannabinoid Precursor in Neurons and Its Control by Calcium and cAMP," J. Neurosci., (1996), Vol. 16, pp. 3934-3942.	
	48.	CADAS, H. et al., "Occurrence and Biosynthesis of Endogenous Cannabinoid Precursor, N-Arachidonoyl Phosphatidylethanolamine, in Rat Brain," J. Neurosci., (1997), Vol. 17, No. 4, pp. 1228-1242.	
	49.	CALIGNANO, A. et al., "Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide" Eur. J. Pharmacol. 419(2-3):191-8 (2001)	
	50.	CALIGNANO, A. et al., "Bidirectional control of airway responsiveness by endogenous cannabinoids," Natura, (2000), Vol. 406, pp. 96-101.	
	51.	CALIGNANO, A. et al., "Control of pain initiation by endogenous cannabinoids," Nature, (1998), Vol. 394, pp. 277-281.	
	52.	CHAPMAN, K., "Emerging physiological roles for N-acylphosphatidylethanolamine metabolism in plants: signal transduction and membrane protection," Chem. Phys. Lipids, (2000), Vol. 108:22, pp. 221-229.	
	53.	CHAWLA, A. et al., "Nuclear receptors and lipid physiology: opening the X-files" Science 294:1968-70 (2001)	
	54.	COLVILLE-NASH, P. et al., "Inhibition of inducible nitric oxide synthase by peroxisome proliferators-activated receptor agonists: correlation with induction of heme oxygenase 1" J. Immunology 161:978-984 (1998)	
	55.	CONTI, S. et al., "Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabiximol in a model of acute inflammation in the rat," British Journal of Pharmacology, (2002), Vol. 135, pp. 181-187.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/642,462		
		Filing Date	August 15, 2003		
		First Named Inventor	Piomelli, Daniele		
		Art Unit	1623		
		Examiner Name	To Be Assigned		
Sheet	4	of	6	Attorney Docket Number	02307E-125510US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	56.	CRAVATT, B. et al., "Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides" Nature 384:63-67 (1996)		
	57.	CRAVATT, B. et al., "Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase," PNAS, (2001), Vol. 98, No. 16, pp. 9371-9376.		
	58.	DESARNAUD, F. et al., "Anandamide Amidohydrolase Activity in Rat Brain Microsomes," J. Biol. Chem., (1995), Vol. 270, No. 11, pp. 6030-6035.		
	59.	DESERGNE, B. et al., "Peroxisome proliferator-activated receptors: Nuclear control of metabolism" Endocrine Rev. 20(5):649-688 (1999)		
	60.	DEVANE, W. et al., "Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor," Science, (1992), Vol. 258, pp. 1946-1949.		
	61.	DI MARZO, V. et al., "Formation and inactivation of endogenous cannabinoid anandamide in central neurons," Nature, (1994), Vol. 372, pp. 686-691.		
	62.	DI TOMASO, E. et al., "Brain cannabinoids in chocolate" Nature 382(Aug. 22):677 (1996)		
	63.	DI TOMASO, E. et al., "Endogenous lipids that activate cannabinoid receptors. Formation and inactivation" Adv. Exp. Med. Biol. 407:335-40 (1997)		
	64.	FORMAN, B. et al., "Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ ," PNAS, (1997), Vol. 94, pp. 4312-4317.		
	65.	FU, J. et al., "Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR- α ," Nature 425(6953):90-3 (2003)		
	66.	GAETANI, S. et al., "Modulation of meal pattern in the rat by the anorexic lipid mediator oleylethanolamide" Neuropsychopharm. 28(7):1311-6 (2003)		
	67.	GIUFFRIDA, A. and D. PIOMELLI, "Purification and High-Resolution Analysis of Anandamide and Other Fatty Acylethanolamides," in S. G. Laychock, ed. and R. P. Rubin, ed. Lipid Second Messengers, CRC Press LLC, Boca Raton, Florida, (1999), pp. 113-133.		
	68.	GIUFFRIDA, A. et al., "Dopamine activation of endogenous cannabinoid signaling in dorsal striatum," Nat. Neurosci., (1999), Vol. 2, No. 4, pp. 358-363.		
	69.	GIUFFRIDA, A. et al., "Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma," FEBS Letters, (1998), Vol. 422, pp. 373-376.		
	70.	GIUFFRIDA, A. et al., "Mechanisms of Endocannabinoid Inactivation: Biochemistry and Pharmacology," J. Pharmacol. Exp. Ther., (2001), Vol. 298, No. 1, pp. 7-14.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known			
		Application Number	10/642,462		
		Filing Date	August 15, 2003		
		First Named Inventor	Piomelli, Daniele		
		Art Unit	1623		
		Examiner Name	To Be Assigned		
Sheet	5	of	6	Attorney Docket Number	02307E-125510US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T 2
	71.	GIUFFRIDA, A. et al., "Quantification of Bioactive Acylethanolamides in Rat Plasma by Electrospray Mass Spectrometry," Anal. Biochem., (2000), Vol. 280, pp. 87-93.		
	72.	GOMEZ, R. et al., "A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding" J. Neurosci. 22(21):9612-7 (2002)		
	73.	GRIFFIN, G. et al., "Cloning and Pharmacological Characterization of the Rat CB2 Cannabinoid Receptor," J. Pharmacol. Exp. Ther., (2000), Vol. 292, No. 3, pp. 686-694.		
	74.	HASSON, M. "The effect of low caloric diet on panamide [oleylethanolamide (OEA)] response in obese and non-obese adults" UCI Medical Center Clinical Trials Web Page- Standard Research Recruitment Advertisement Format		
	75.	JANERO, D., "Nutritional aspects of nitric oxide: human health implications and therapeutic opportunities" Nutrition 17:896-903 (2001)		
	76.	KATHURIA, S. et al., "Modulation of anxiety through blockade of anandamide hydrolysis" Nature Medicine 9(1):76-81 (2003)		
	77.	KERSTEN, S. et al., "Roles of PPARs in health and disease" Nature 405:421-424 (2000)		
	78.	KHANOLKAR, A. et al., "Structure-Activity Relationships of Anandamide, and Endogenous Cannabinoid Ligand," Life Sci., (1999), Vol. 65, No. 6/7, pp. 607-616.		
	79.	KLIEWER, S. et al., "Peroxisome proliferators-activated receptors: from genes to physiology" Recent Prog Horm Res 56 239-43 (2001)		
	80.	LOVISCACH, M. et al., "Distribution of peroxisome proliferators-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action" Diabetologia 43(3):304-11 (2000)		
	81.	MECHOULAM, R. et al., "A hunger for cannabinoids" Nature 410:763-765 (2001)		
	82.	MEMON, R. et al., "Up-regulation of peroxisome proliferators-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice" Endocrinology 141(11):4021-31 (2000)		
	83.	MOYA-CAMARENA, S. et al., "Conjugated linoleic acid activates peroxisome proliferators-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats" Biochim Biophys Acta 1436(3):331-42 (1999)		
	84.	MUDALIAR, S. and R. HENRY, "PPAR agonists in health and disease: a pathophysiologic and clinical overview" Current Opin. Endocrin. Diabet. 9:285-302 (2002)		
	85.	PIOMELLI et al., "Structural determinants for recognition and translocation by the anandamide transporter", Proc. Natl. Acad. Sci. USA, May 1999; Vol. 96; pp. 5802-5807		
	88.	PIOMELLI, D. et al., "The endocannabinoid system as a target for therapeutic drugs" Trends Pharmacol. Sci. 21(6):218-24 (2000)		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/642,462
		<i>Filing Date</i>	August 15, 2003
		<i>First Named Inventor</i>	Piomelli, Daniele
		<i>Art Unit</i>	1623
		<i>Examiner Name</i>	To Be Assigned
		<i>Attorney Docket Number</i>	02307E-125510US
Sheet	6	of	6

(use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	87.	PIOMELLI, D. et al., "Endogenous Cannabinoid Signaling," Neurobiol. Dis., (1998), Vol. 5, pp. 462-473 (1998).	
	88.	QUISTAD, G. et al., "Fatty Acid Amide Hydrolase Inhibition by Neurotoxic Organophosphorus Pesticides," Toxicology and Applied Pharmacology, (2001), Vol. 173, pp. 48-55.	
	89.	QUISTAD, G. et al., "Selective Inhibitors of Fatty Acid Amide Hydrolase Relative to Neuropathy Target Esterase and Acetylcholinesterase: Toxicological Implications," Toxicology and Applied Pharmacology, (2002), Vol. 179, pp. 57-63.	
	90.	RALOFF, J. "Science News Online- Food for Thought: 'Prescription-strength chocolate' at < http://www.sciencenews.org/sn_arch/10_12_96/food.htm > (Visited September 10, 2003)	
	91.	RINALDI-CARMONA et al., "Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist" Life Sci., 56:1941-1947 (1995)	
	92.	REGENTS OF THE UNIVERSITY OF CALIFORNIA, "Natural, marijuana-like chemical may provide treatment for obesity- Study in Nature shows reduced feeding, weight gain" at < http://www.ucsfhealth.com/News/Releases/obesity_marijuana.htm > November 7, 2001	
	93.	RODRIGUEZ de FONSECA, F. et al., "An anorectic lipid mediator regulated by feeding," Nature, (2001) Vol. 414, pp. 209-212.	
	94.	SCHMID, H. et al., "The N-acylation-phosphodiesterase pathway and cell signalling," Chem. Phys. Lipids, (1996), Vol. 60, pp. 133-142.	
	95.	SCHMID, P. et al., "Properties of Rat Liver N-Acylethanolamine Amidohydrolase," J. Biol. Chem., (1985), Vol. 260, No. 26, pp. 14145-14149.	
	96.	SCHOONJANS, K. et al., "The peroxisome proliferators activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation" Biochim Biophys Acta 1302 (2):93-109 (1996)	
	97.	STELLA, N. et al., "Receptor-dependent formation of endogenous cannabinoids in cortical neurons" Eur. J. Pharmacol. 425(3):189-96 (2001)	
	98.	STICKER-KRONGRAD et al., "Nitric oxide mediates hyperphagia of obese Zucker rats: relation to specific changes in the microstructure of feeding behavior" Life Sci. 58:PL9-15 (1996)	
	99.	WILLSON, T. et al., "The PPARs: From Orphan Receptors to Drug Discovery," Journal of Medicinal Chemistry, (2000), Vol. 43, No. 4, pp. 527-550.	

60158249 v1

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.